Navigation Links
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

etitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.  Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the FDA for the products.  The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.  Only the FDA can determine whether the products are safe and effective for these uses.  Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
2. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
3. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
4. Amgen Announces Webcast of 2013 First Quarter Financial Results
5. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
6. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
7. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
8. Selexis Announces Expansion of R&D License Agreement with Amgen
9. Amgen Outlines Long-Term Strategy
10. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
11. Amgen To Webcast 2013 Business Review Meeting On February 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... BOSTON , May 22, 2015  In a ... in the U.S., T1D Exchange researchers conclude ... in type 1 diabetes across all age groups, but ... the most up-to-date picture of diabetes treatment, underscoring the ... therapies and technologies that can help type 1 patients ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
(Date:5/21/2015)... CITY, Calif. , May 21, 2015  Cardica, Inc. ... 2015, new employee Greg Watson , the company,s vice ... shares of the company,s common stock, at a per share ... 20, 2015. The stock option was granted pursuant to Cardica, ... of directors in May 2015 under Rule 5653(c)(4) of the ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... a clinical study of adults, VYVANSE taken once-daily ... PHILADELPHIA, Oct. 7 Shire plc (LSE: ... that a study published in the September issue ... significantly improved,Attention Deficit Hyperactivity Disorder (ADHD) symptoms in ...
... - Data Presented Today at ACG Annual Scientific ... Ironwood,Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories,Inc. ... of results from a Phase,2b study assessing linaclotide,s ... syndrome with constipation (IBS-C). Analysis of the data,indicates ...
Cached Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5
(Date:5/22/2015)... Carnegie Science Center and ... partnership to develop BodyTech, a dynamic, three-pronged health and ... a new exhibit at the Science Center called BodyWorks, ... new traveling science show, Anatomy Adventure, which will hit ... Designed to explore a wide range of topics surrounding ...
(Date:5/22/2015)... May 22, 2015 Power Systems is proud ... the 2015 race season. Drobeck is in his second year ... a firefighter with the Missoula Fire Department in Missoula, MT. ... Pro in 2014. During his career, he has had 15 ... Drobeck recorded top 10 finishes in all seven of his ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... A Phase 3 French study, which ... Clinical Oncology (ASCO)’s annual meeting at the end ... patients who received bevacizumab in addition to the ... Genentech, Inc.) is an antibody that blocks angiogenesis ... used to treat many other cancers, including lung ...
(Date:5/22/2015)... 22, 2015 In an effort to ... Sons is offering to donate $5 dollars for every ... unit or water softening system. Customers have their needs ... Sons gets business; and the Special Olympics receives money. ... Olympics helps over 4.4 million athletes, and boasts a ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... the aim to combat AIDS will exploit the unused power ... to aid research and identify drugs used to combat the ... called FightAIDS@Home, aims to enlist about 100,000 computer users to ... when they would otherwise be idle., ,This ...
... to protect Americans from bird flu and other diseases, ... and shipping firms to hand over// passenger and crew ... illnesses., ,The Atlanta-based Centers for Disease Control and ... responding to health threats, has proposed the regulatory overhaul. ...
... duration of breast-feeding is associated with reduction in risk ... Previous studies have already provided evidence for improved insulin ... to their counterparts. ,The study is the first ... between lactation and Type 2 diabetes. More than 1,57,003 ...
... Conservative groups in the United States, who had voiced ... "morning-after" pill, are now having no such qualms about ... manufactured by Merck & Co. and GlaxoSmithKline are still ... the market, but concerns had been voiced about them ...
... Rs 300 million to Christian Medical College (CMC), Vellore, to ... see if stem cells can be developed into heart muscles, ... specialized cells. , ,"It is a matter of great ... project. It will have far-reaching implications in the lives of ...
... Mayo Clinic, in Olmsted County, Minnesota, suggest that Parkinson's ... manual workers,// meaning that an individual's educational and career ... ,The researchers said that probably early Parkinson's triggered a ... than long periods of education increasing susceptibility to the ...
Cached Medicine News:Health News:U.S. To Tighten Sick Passenger, Quarantine Rules 2Health News:Breastfeeding To Reduce Risk Of Type 2 Diabetes 2Health News:Religious groups overcome objections to cervical cancer vaccines 2
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
... The Diagnostic Automation, Inc.. (DAI) Measles IgG ... the detection and quantitative determination of IgG ... sera. Individual serum specimens may be ... Paired sera, acute and convalescent, may be ...
The DSL-05-10-MEG Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Measles Virus in human serum. This assay is intended fo...
... The Vitros Cortisol Range Verifiers have ... System with,the Vitros Immunodiagnostic Products Cortisol Reagent ... range verifiers contain low and,high cortisol concentrations, ... range, and can be used,to verify measurement ...
Medicine Products: